Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Harvard Business School
Express Scripts
Moodys
AstraZeneca

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Rilapladib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Rilapladib?

Rilapladib is an investigational drug.

There have been 4 clinical trials for Rilapladib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2011.

The most common disease conditions in clinical trials are Alzheimer Disease, Atherosclerosis, and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

Recent Clinical Trials for Rilapladib
TitleSponsorPhase
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy VolunteersGlaxoSmithKlinePhase 1
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's DiseaseGlaxoSmithKlinePhase 2
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 WeeksGlaxoSmithKlinePhase 2

See all Rilapladib clinical trials

Clinical Trial Summary for Rilapladib

Top disease conditions for Rilapladib
Top clinical trial sponsors for Rilapladib

See all Rilapladib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKesson
AstraZeneca
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.